Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of 15.00% is 182% above its 5-year average of -18.26%, near the high end of its 5-year range (-51.94%–16.34%).
3.95% above its 12-month average of 14.43%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): 0.90%.
RETURN ON ASSETS (ROA)
15.00%
RETURN ON ASSETS (ROA) AVG TTM
14.43%
RETURN ON ASSETS (ROA) AVG 3Y
-2.68%
RETURN ON ASSETS (ROA) AVG 5Y
-18.26%
RETURN ON ASSETS (ROA) AVG 10Y
-28.73%
RETURN ON ASSETS (ROA) AVG 15Y
-31.68%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+3.95%
CURRENT VS 3Y AVG
+659.70%
CURRENT VS 5Y AVG
+182.15%
CURRENT VS 10Y AVG
+152.21%
CURRENT VS 15Y AVG
+147.34%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+146.53%
vs the sector median at left
Niagen Bioscience Inc
Market Cap
$212.25M
Return on Assets (ROA)
15.00%
TTM Avg
14.43%
3Y Avg
-2.68%
5Y Avg
-18.26%
Market Cap
$212.75M
Return on Assets (ROA)
-79.86%
TTM Avg
-75.29%
3Y Avg
-50.35%
5Y Avg
-41.02%
Market Cap
$213.78M
Return on Assets (ROA)
-31.94%
TTM Avg
-71.44%
3Y Avg
-59.77%
5Y Avg
-50.19%
Market Cap
$210.85M
Return on Assets (ROA)
25.43%
TTM Avg
5.08%
3Y Avg
-10.27%
5Y Avg
-14.74%
Market Cap
$210.24M
Return on Assets (ROA)
21.17%
TTM Avg
16.86%
3Y Avg
29.92%
5Y Avg
34.25%
Market Cap
$210.02M
Return on Assets (ROA)
-55.47%
TTM Avg
-12.81%
3Y Avg
-16.15%
5Y Avg
-23.71%
Market Cap
$208.63M
Return on Assets (ROA)
18.34%
TTM Avg
16.50%
3Y Avg
12.68%
5Y Avg
11.55%
Market Cap
$208.59M
Return on Assets (ROA)
-34.38%
TTM Avg
-28.15%
3Y Avg
-48.34%
5Y Avg
-48.34%
Market Cap
$218.04M
Return on Assets (ROA)
-28.91%
TTM Avg
-2.34%
3Y Avg
-20.04%
5Y Avg
-20.00%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Niagen Bioscience Inc (NAGE) | $212.25M | 15.00% | 14.43% | -2.68% | -18.26% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $212.75M | -79.86% | -75.29% | -50.35% | -41.02% |
| Prelude Therapeutics Incorporated (PRLD)vs › | $213.78M | -31.94% | -71.44% | -59.77% | -50.19% |
| Compugen Ltd. (CGEN)vs › | $210.85M | 25.43% | 5.08% | -10.27% | -14.74% |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $210.24M | 21.17% | 16.86% | 29.92% | 34.25% |
| Entrada Therapeutics, Inc. (TRDA)vs › | $210.02M | -55.47% | -12.81% | -16.15% | -23.71% |
| Pro-Dex, Inc. (PDEX)vs › | $208.63M | 18.34% | 16.50% | 12.68% | 11.55% |
| Sionna Therapeutics, Inc. (SION)vs › | $208.59M | -34.38% | -28.15% | -48.34% | -48.34% |
| Keros Therapeutics, Inc. (KROS)vs › | $218.04M | -28.91% | -2.34% | -20.04% | -20.00% |
| Electra Therapeutics Inc. (ETRA)vs › | $205.44M | N/A | N/A | N/A | N/A |
ROA
15.0%
ROE
19.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | 16.34% |
| 2024-12-31 | 12.52% |
| 2023-12-31 | -8.98% |
| 2022-12-31 | -30.60% |
| 2021-12-31 | -46.90% |
| 2020-12-31 | -51.94% |
| 2019-12-31 | -79.87% |
| 2018-12-31 | -78.89% |
| 2017-12-31 | -18.14% |
| 2016-12-31 | -14.82% |
| 2015-12-31 | -14.78% |
| 2014-12-31 | -46.79% |
| 2013-12-31 | -49.18% |
| 2012-12-31 | -129.09% |
| 2011-12-31 | -125.92% |
| 2010-12-31 | -31.53% |
| 2009-12-31 | -25.46% |
| 2008-12-31 | -51.54% |
| 2007-12-31 | -6617.59% |
